Use of fructosyltransferase
AssigneeInulox Ltd.
InventorsAndreas Kjaer, Niels Wicke, Carolin Schulte, Joel Kosmin, Joshua Sauer
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for reducing fructose uptake in a subject; as well as associated compositions. The compositions are useful in therapeutic and non-therapeutic uses such as appetite suppression and treating or preventing metabolic syndrome, obesity, non-alcoholic fatty liver disease, and constipation.
Claims41
An in vivo method of reducing fructose uptake in a subject, the method comprising administering to the subject an isolated fructosyltransferase.
An in vivo method of reducing the formation of fructose via metabolism of sucrose in a subject, the method comprising administering to the subject an isolated fructosyltransferase.
An in vivo method of reducing glucose uptake and/or of reducing the formation of glucose via metabolism of sucrose in a subject, the method comprising administering to the subject an isolated fructosyltransferase.
A method according to any one of the preceding claims, which is a method of producing a fructooligosacharide in a subject in vivo, the method comprising administering to the subject an isolated fructosyltransferase and thereby converting sucrose to said fructooligosacharide
A method according to any one of the preceding claims, wherein said fructosyltransferase is an inulosucrase or a levansucrase.
A method according to any one of the preceding claims, wherein said fructosyltransferase is an inulosucrase of EC class 2.4.1.9.
A method according to any one of the preceding claims, which is a method of reducing fructose uptake in a subject and producing inulin in vivo, the method comprising administering to the subject an isolated inulosucrase and thereby converting sucrose to inulin in vivo.
A method according to any one of the preceding claims which is a method of reducing the formation of fructose via metabolism of sucrose in a subject and producing inulin in vivo, the method comprising administering to the subject an isolated inulosucrase and thereby converting sucrose to inulin in vivo.
A method according to any one of the preceding claims, wherein said fructosyltransferase comprises a polypeptide according to any one of SEQ ID NOs:
- 1 to 10 or a functional variant thereof.
A method according to any one of the preceding claims, wherein said fructosyltransferase has:
- i) at least 70% homology to SEQ ID NO:
- 1, wherein said homology is assessed relative to positions 128, 129, 153, 158, 159, 160, 162, 196, 197, 281, 282, 298, 379, 381, 399, 402, 457, 458 and 480 of SEQ NO:
- 1;
- or
- ii) at least 70% homology to SEQ ID NO:
- 5, wherein said homology is assessed relative to positions 49, 50, 73, 82, 83, 84, 85, 86, 119, 120, 209, 210, 293, 295 and 361 of SEQ ID NO:
- 5;
- or
- iii) at least 70% homology to SEQ ID NO:
- 8, wherein said homology is assessed relative to positions 54, 55, 56, 57, 58, 59, 74, 75, 116, 265, 338, 339, 366, 370, 372 and 373 of SEQ ID NO:
- 8.
A method according to any one of the preceding claims, wherein said fructosyltransferase comprises alanine at the position corresponding to A182 of SEQ ID NO:
- 1.
A method according to any one of the preceding claims, wherein said fructosyltransferase comprises phenylalanine at the position corresponding to F372 of SEQ ID NO:
- 8 and/or comprises glycine at the position corresponding to G373 of SEQ ID NO:
- 8.
A method according to any one of the preceding claims, wherein said fructosyltransferase has a solubility GRAVY score of −0.4 or more negative than −0.4.
A method according to any one of the preceding claims, wherein said fructosyltransferase is derived from an organism of genus Lactobacillus, Bacillus, Leuconostoc, Streptomyces, Aspergillus, or Clostridium.
A method according to any one of the preceding claims, wherein said fructosyltransferase is derived from an organism of species Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus reuteri, Bacillus agaradhaerens, Bacillus amyloliquefaciens, Bacillus megaterium, Bacillus subtilis, Leuconostoc citreum, Leuconostoc mesenteroides, Streptomyces viridochromogenes, Aspergillus acelatus, Aspergillus sydowii, or Clostridium acetobutylicum.
A method according to any one of the preceding claims, wherein said fructosyltransferase is expressed by or is obtainable by expression from an organism of genus Escherichia, Lactobacillus, Saccharomyces, Bacillus, Pichia, Trichoderma or Aspergillus;
- preferably E. coli, S. cerevisiae, B. subtilis, P. pastoris, T reesei, A. niger, or A. oryzae.
A method according to any one of the preceding claims, wherein the fructosyltransferase is comprised in a nutraceutical composition comprising said fructosyltransferase and one or more nutraceutically acceptable filler, stabilizing agent, coloring agent or flavouring agent.
A method according to any one of the preceding claims, comprising orally administering said fructosyltransferase or said nutraceutical composition to said subject.
A method according to any one of the preceding claims, wherein said method is a non-therapeutic method;
- preferably wherein said method does not comprise the treatment of the human or animal body by therapy or surgery.
An isolated fructosyltransferase for use in
- i) reducing fructose uptake in a subject,
- ii) reducing the formation of fructose via metabolism of sucrose in a subject;
- iii) reducing glucose uptake and/or of reducing the formation of glucose via metabolism of sucrose in a subject;
- iv) producing a fructooligosacharide in a subject, said use comprising administering to the subject an isolated fructosyltransferase and thereby converting sucrose to said fructooligosacharide;
A nutraceutical composition comprising an isolated fructosyltransferase and one or more nutraceutically acceptable filler, stabilizing agent, colouring agent or flavouring agent.
A pharmaceutically acceptable composition comprising an isolated fructosyltransferase and one or more pharmaceutically acceptable carrier, excipient, or diluent.
A food composition or foodstuff comprising an isolated fructosyltransferase and one or more carbohydrate, fat, lipid, flavouring agent, or colouring agent.
Dependencies are inferred from the claim text.